Zhejiang Xinguang Pharmaceutical Co., Ltd. (SHE:300519)
14.10
-0.31 (-2.15%)
Sep 10, 2026, 3:04 PM CST
SHE:300519 Revenue
Zhejiang Xinguang Pharmaceutical had revenue of 54.12M CNY in the quarter ending June 30, 2026, with 13.48% growth. This brings the company's revenue in the last twelve months to 267.01M, up 1.76% year-over-year. In the year 2025, Zhejiang Xinguang Pharmaceutical had annual revenue of 265.36M, down -0.86%.
Revenue (ttm)
267.01M
Revenue Growth
+1.76%
P/S Ratio
8.63
Revenue / Employee
864.11K
Employees
309
Market Cap
2.31B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 265.36M | -2.30M | -0.86% |
| Dec 31, 2024 | 267.66M | -2.74M | -1.01% |
| Dec 31, 2023 | 270.40M | -81.09M | -23.07% |
| Jan 1, 2023 | 351.49M | 30.61M | 9.54% |
| Jan 1, 2022 | 320.88M | 37.80M | 13.35% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ShanXi C&Y Pharmaceutical Group Co.,LTD. | 849.67M |
| Zhejiang Shengda Bio-Pharm | 832.86M |
| Enwei Pharmaceutical | 826.13M |
| Jiangxi Synergy Pharmaceutical | 784.40M |
| Hainan Huluwa Pharmaceutical Group | 634.04M |
| Chengdu huasun technology group Inc. , LTD. | 486.70M |
| Zhejiang Shapuaisi Pharmaceutical | 423.20M |
| Anhui Huangshan Capsule | 407.10M |